Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

Despite the development of predictive biomarkers to shape treatment paradigms and outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) remains an issue of concern. We explored clinical factors in 332 advanced NSCLC who received EGFR TKI and molecular characteristics thro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sitthideatphaiboon, Piyada, Teerapakpinyo, Chinachote, Korphaisarn, Krittiya, Leelayuwatanakul, Nophol, Pornpatrananrak, Nopporn, Poungvarin, Naravat, Chantranuwat, Poonchavist, Shuangshoti, Shanop, Aporntewan, Chatchawit, Chintanapakdee, Wariya, Sriuranpong, Virote, Vinayanuwattikun, Chanida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828869/
https://www.ncbi.nlm.nih.gov/pubmed/35140316
http://dx.doi.org/10.1038/s41598-022-06239-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828869/
https://www.ncbi.nlm.nih.gov/pubmed/35140316
http://dx.doi.org/10.1038/s41598-022-06239-y

Ejemplares similares